Login to Your Account

The Challenge of a New Vaccine

High ‘Cholera Sell’? Vouching for Paxvax’s Phase III Strategy

By Randy Osborne
Staff Writer

Monday, September 9, 2013

Paxvax Inc.’s just-begun Phase III effort with PXVX0200 could lead to the first cholera vaccine approved for marketing in the U.S., and the company could become the first to gauge the resale value of the FDA’s priority review voucher (PRV), an incentive put in place six years ago to boost work against neglected tropical diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription